



## NEVIRAPINE LOADED MESOPOROUS SILICA NANOPARTICLES (MSNPS) BASED DRUG DELIVERY SYSTEM (DDS) FOR DELIVERY FOR ANTI HIV-1 THERAPY – A STUDY

Pratik Nandi<sup>1</sup>, Dr. Sangita Gupta<sup>2</sup>

Department of Microbiology

<sup>1,2</sup>OPJS University, Churu, Rajasthan

### Abstract

HIV is often a highly contagious virus that may be transmitted by contact with or movement of serum, pre-ejaculate, body fluids, or cervical mucus. The primary objective of the study is to develop a drug delivery system (DDS) for anti-HIV treatment using nevirapine (NVP) loaded mesoporous silica nanoparticles. NVP was mixed with populated in dimethyl sulphoxide (DMSO) at a 1:2 relative density for nevirapine (NVP) loading MSNPs. The quantity of medicine in the solution was calculated using a sensitivity measurement at 296 nm. The surface interaction of produced nanoparticles with other pharmacological compounds employed in the manufacture of nano-ART/s was investigated using the Fourier Transform Infrared Spectroscopy (FT-IR). After each experiment is conducted in pairs, residuals-based methods will be calculated. The findings demonstrated that NVP, all of the medicines, constantly released at both pH levels throughout the study. All medications released more readily as the pH reached 6.8. After 48 hours and 144 hours, respectively, for NVP, a collective clearance of around 32% and 62% was observed. Many NPs have been successfully manufactured to deliver a range of medications with the use of nanomedicine, a cutting-edge technology. They provide decreased systemic toxicity, increased drug loading, improved therapeutic effectiveness, and better bioavailability at a lower dose of medications needed for therapy.

**Keywords:** *Nevirapine, Mesoporous silica nanoparticles (MSNPs), Drug delivery system (DDS), nanomedicine.*

### Introduction

Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) is still one of the biggest risks to world health, according to Boyapalle et al. (2012). HIV is often a highly infectious virus that is spread by touching or movement of serum, pre-ejaculate, bodily fluids, and cervical mucus. According to a study, condom-free sexual contact cannot transmit The virus as long as one person has a persistently suppressed immunogenicity (Rodger et al., 2019). There are currently no HIV vaccinations available to help prevent HIV infection. Gels, creams, rings, and films are now being used in microbicide studies to stop the sexual transmission of HIV, and efforts are also being made to investigate various kinds of "delivery" methods (Kim et al., 2022).

Despite substantial improvements in HIV/AIDS management, a large number of obstacles to overcome (Kim et al., 2022). As a result, nanoemulsions are being used to produce HIV/AIDS therapies. The use of nanotechnology for targeted administration and delayed, sustained release of medicines, proteins, peptides, or nucleic acids through any channel to optimise efficacy and reduce side effects has been extensively studied for safety and lack of toxicity. One of the most significant areas of nanomedicine research is the use of



nanotechnology to target medications and macromolecules to certain tissues or cells (Sagar et al., 2014). As of now, nanoparticles provide a solid foundation for combining protein- and DNA-based vaccines and microbicides, and they will make future manufacture, preclinical testing, and clinical trials easier. The aim of the study is to develop a drug delivery system (DDS) for anti HIV-1 therapy Nevirapine loaded Mesoporous silica nanoparticles (MSNPs).

## Material and method:

### Preparation and development of Nevirapineloaded MSNPs

For Nevirapine (NVP) Loading MSNPs, NVP was combined with Populated in DMSO at a relative density of 1:2. After 24 hours of stirring, alcohol non-international armed were pelletized by revolving the combination for 25 minutes at 14,000 rpm. To get rid of the free medicine, the pellet was rinsed three times. A measurement of sensitivity at 296 nm was used to calculate the amount of medication in the solution. For later usage, NVP-MSNPs were kept frozen. Math was used to compute the absorption.

$$I\text{-Loading capacity (\%)} = (Total\ drug - drug\ in\ supernatant) / (total\ drug) \times 100$$

..... Equation (I)

### Fourier Transform Infrared Spectroscopy (FT-IR)

The FT-IR was used to study the surface interaction between synthesized nanoparticles with other drug molecules involved in the synthesis of nano-ART/s.

### Data analysis

Methods with residuals will be computed for each experiment after it will be carried out in pairs. One-way ANOVA was used to assess the analytical significance of distinctions Utilizing the programme Data are presented as the mean with a 95 percent of overall coefficient of determination, and discrepancies were judged serious when  $p < 0.05$ .

### Result and Discussion


MSNPs possess different qualities such as a large surface area, simplicity in alteration, and low cytotoxicity. An effort was made to construct MSNPs-based DDS employing HIV-1 non-nucleoside HIV-1 reverse transcriptase inhibitors, NVP in order to take advantage of these advantages. As mentioned previously, silica is considered to be GRAS by US-FDA (Watermann and Brieger, 2017).

Table 1: Anti HIV Assay of NVP

Sr. No	Compound Name	Anti-HIV1 Assay TZM-bl Cells				Anti-HIV1 Assay PBMCS			
		IC50 HIV1VB28 (R5) ( $\mu\text{g/mL}$ )	TI HIV1VB28 (R5)	IC50 HIV1UG070 (X4) ( $\mu\text{g/mL}$ )	TI HIV1UG070 (X4)	IC50 HIV1VB28 (R5) ( $\mu\text{g/mL}$ )	TI HIV1VB28 (R5)	IC50 HIV1UG070 (X4) ( $\mu\text{g/mL}$ )	TI HIV1UG070 (X4)
1	MSNP	1.190 $\pm$ 0.71	143.722	18.195 $\pm$ 1.21	14.535	2.397 $\pm$ 0.09	402.274	21.427 $\pm$ 2.19	26.312
2	NVP	0.18 $\pm$ 0.05	1827.33	0.105 $\pm$ 0.03	2436.43	0.187 $\pm$ 0.001	1483.97	0.140 $\pm$ 0.004	2543.95

In both; TZM-bl cells and PBMCs, it was observed that there was a significant decrease in the IC<sub>50</sub> value for NVP-MSNPs in comparison to free NVP. The lesser IC<sub>50</sub> value of NVP-MSNPs in addition to effective reduction in the CC<sub>50</sub> resulted in the achievement of higher TI in comparison to free NVP.

An important test to evaluate the quality, protection, and effectiveness of nanofiber DDS consists of an in vivo performance study. Given that the lymph nodes' pH is confirmed to have a pH of 6.8, the dissolution rate was expected to be at these levels (Wu et al., 2019). The results showed that all of the drugs—NVP—released continuously throughout the trial at both pH levels. At pH 6.8, a greater release of all medicines was observed. For NVP, a collective clearance of around 32% was seen after 48 hours and 62% after 144 hours. Fig. 1. However, as relative to NVP showed a lower drug release pattern. In addition, the molecule of NVP contains just a few electron rich aromatic ring. As a consequence, lower engagement involving MSNPs and NVP was caused by complex formation of these sites, allowing for increased leakage at acidic medium.



**Figure 1:** Release profiles of NVP

The present constraints regarding NVP in ARTs, which including inadequate cell viability of the medication and increased toxicity owing to the delivery of greater doses to the patients, were taken into consideration when this technique was chosen. The previously disclosed approach was used to synthesis the MSNPs, which were around 50 nm in size (Kumar et al., 2017). The porous characteristic of MSNPs, allowed for high loading on NVP to stop drug delivery of the medication to minimum levels, which significantly reduced NVP toxicity. The MSNPs received a huge positive conductivity after being metacognitive strategies with linkers. The MSNPs' successful interaction with the cell membrane was made possible by their positive surface charge, which also made it easier for cells to absorb them. The cellular absorption of MSNPs revealed significant dispersion of MSNPs throughout the cytosol upon



internalisation, which is the location for NVP's action as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Electrically charged nanoscale interacting with present on the cell borders may also be responsible for this behaviour. Furthermore, cell death and the inhibition of proliferating may both contribute to the decrease in cell quantity (Murugesan et al., 2014).

The enhanced absorption of MSNPs through into cells, which resulted in a larger density of NVP inside this nucleus, may be the cause of the enhancement in NVP's anti-HIV1 activity after reloading into Populated (NVP-MSNPs). The pro government effectiveness of NVP was maintained while the neurotoxicity of NVP-MSNPs was dramatically decreased to specific elements (bare/free MSNPs), leading to a large increase in NVP transcriptase inhibitor. These findings imply that treating individuals who have loaded on MSNPs with a lower dosage of NVP could be advantageous and lessen negative effects. Similarly, MSNPs shown almost equivalent inhibitory action against HIV-1 infection compared to NVP, so encouraged researchers to look into how it may block the DNA polymerase process.

## **Conclusion**

With the help of nanomedicine, a cutting-edge technology, a variety of NPs have been successfully synthesized to deliver various drugs. They offer a lower dosage of drugs required for treatment, lower systemic toxicity, higher drug loading, an enhanced therapeutic efficacy, and better bioavailability, however, It has not yet been satisfactorily determined how NPs cause poison. As a result, current research is on creating innovative, multi-functional DDS and starting targeted delivery with lower toxicity. The efficient implementation of a prescription medication to target region necessitates both a suitable graphene and an efficient route of intravenous therapy that allows the medicine to cross intrinsic limitations (such as the blood brain barrier) or extend remote computers (such as the central nervous system).



## References

- 1) Boyapalle, S., Mohapatra, S., & Mohapatra, S. (2012). Nanotechnology applications to HIV vaccines and microbicides. *Journal of global infectious diseases*, 4(1), 62.
- 2) Kim, J. T., Zhang, T. H., Carmona, C., Lee, B., Seet, C. S., Kostelny, M., ... & Zack, J. A. (2022). Latency reversal plus natural killer cells diminish HIV reservoir in vivo. *Nature communications*, 13(1), 1-14.
- 3) Kumar, P., Tambe, P., Paknikar, K. M., & Gajbhiye, V. (2017). Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: a comparative study. *Colloids and Surfaces B: Biointerfaces*, 156, 203-212.
- 4) Murugesan, V., Makwana, N., Suryawanshi, R., Saxena, R., Tripathi, R., Paranjape, R., ... & Katti, S. B. (2014). Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorganic & medicinal chemistry*, 22(12), 3159-3170.
- 5) Rodger, A. J., Cambiano, V., Bruun, T., Vernazza, P., Collins, S., Degen, O., ... & Pechenot, V. (2019). Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. *The Lancet*, 393(10189), 2428-2438.
- 6) Sagar, V., Pilakka-Kanthikeel, S., Pottathil, R., Saxena, S. K., & Nair, M. (2014). Towards nanomedicines for neuroAIDS. *Reviews in medical virology*, 24(2), 103-124.
- 7) Watermann, A., & Brieger, J. (2017). Mesoporous silica nanoparticles as drug delivery vehicles in cancer. *Nanomaterials*, 7(7), 189.
- 8) Wu, H., Estrella, V., Enriquez-Navas, P., El-Kenawi, A., Russell, S., Abrahams, D., ... & Gillies, R. J. (2019). Lymph nodes inhibit T-cell effector functions locally by establishing acidic niches. *BioRxiv*, 689604.